Response rates, survival status and adverse events of placebo in randomized control trials for hepatocellular carcinoma: A meta-analysis

Figure 4 Forest plot of the incidence of adverse events in the placebo arm across the randomized controlled trials of hepatocellular carcinoma. A: Grade 3 or 4 adverse events (AEs) in the placebo arm; B: Interruption or reductions due to AEs in the placebo arm; C: Treatment discontinuation due to AEs in the placebo arm.